Wearable device aims to unfreeze gait in Parkinson's

NCT ID NCT07675408

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether a wearable device called cueStim can shorten the duration of freezing of gait—a sudden inability to move—in people with Parkinson's disease. About 60 participants, aged 60 to 90, will wear the device for four weeks during daily life and be assigned to one of two device modes. The goal is to see if one mode reduces freezing episodes better than the other.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cueStim wearable device
What this could lead to
If one mode works better, it could offer a non-drug way to reduce freezing-of-gait episodes and improve daily mobility for people with Parkinson's.
What could go wrong
This is an early comparison of two device modes, not a test against a placebo. It is small (60 people) and short (4 weeks), so results may not apply broadly or show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE WITH FREEZING OF GAIT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arrow Clinical Trials

    Daytona Beach, Florida, 32117, United States

  • Emory University

    Atlanta, Georgia, 30329, United States

  • Evergreen Health Research Program

    Kirkland, Washington, 98034, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

    Contact Email: •••••@•••••

  • University of Kansas

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.